Etelcalcetide

Product Description

Specific Disclaimer. This active ingredient could be protected by a patent in force and would be therefore developed on request exclusively for the purposes stated in Article 10.6 of the Directive 2001/83/EC as amended by the Directive 2004/27/EC (Bolar provision). No activity will be performed with the active ingredients protected by a patent in force beyond the scope of the Bolar provision in any concerned jurisdiction. Nothing herein should be construed as an offer or promotion or advertisement for the sale or use of any product, if such sale or use infringes valid patents and is not authorized under applicable laws and regulations. This information is provided to you solely for your evaluation, to determine your interest in a potential relationship with Aspen Oss B.V.

Aspen Oss B.V

  • NL
  • 2015
    On CPhI since
  • 4
    Certificates
  • 500 - 999
    Employees
Manufacturer/Innovator
Specifications
  • CAS Registry Number
    1262780-97-1
  • Supplied from
    Netherlands

Aspen Oss B.V

  • NL
  • 2015
    On CPhI since
  • 4
    Certificates
  • 500 - 999
    Employees
Manufacturer/Innovator

More Products from Aspen Oss B.V

  • Estradiol

    Product Estradiol

    Aspen Oss B.V offers a wide range of products which includes estradiol. Therapeutic category: steroid hormones. Contact us for more information.
  • Norethindrone acetate

    Product Norethindrone acetate

    Aspen Oss B.V offers a wide range of products which includes norethindrone acetate. Therapeutic category: steroid hormones. Contact us for more information.
  • Ethinyl estradiol

    Product Ethinyl estradiol

    Aspen Oss B.V offers a wide range of products which includes ethinyl estradiol. Therapeutic category: steroid hormones. Contact us for more information.
  • Sufentanil citrate

    Product Sufentanil citrate

    This API is part of the FCC product portfolio
  • Sufentanil

    Product Sufentanil

    This API is part of the FCC product portfolio and is available for selected markets only
  • Remifentanil Hydrochloride

    Product Remifentanil Hydrochloride

    This API is part of the FCC product portfolio and is available for selected markets only 
  • Pholcodine

    Product Pholcodine

    this API is part of the FCC product portfolio and is available for selected markets only 
  • Morphine Sulfate

    Product Morphine Sulfate

    This API is part of the FCC product portfolio and is available for selected markets only
  • Morphine Tartrate

    Product Morphine Tartrate

    This API is part of the FCC product portfolio and is available for selected markets only
  • Morphine Hydrochloride

    Product Morphine Hydrochloride

    This API is part of the FCC product portfolio and is available for selected markets only 
  • Fentanyl citrate

    Product Fentanyl citrate

    This API is part of the FCC product portfolio and is available for selected markets only 
  • Fentanyl

    Product Fentanyl

    This API is part of the FCC product portfolio and is available for selected markets only

Aspen Oss B.V resources

  • Sponsored Content Aspen API’s Green answer to peptide synthesis

    Our Green Continuous Liquid Phase Peptide Synthesis (GC-LPPS) combines the advantages of the classical solution-phase synthesis with the solid-phase approach. 
  • Brochure Aspen API Mini Brochure

    A quick tour on  Aspen API. 

    Our APIs are not just any APIs. With quality, compliance and collaboration being part of our DNA, we continuously strive to improve and provide you with the ultimate solution.
  • News Trend Report - Sustainability in Pharma

    While in the past, much of the discussion around sustainability in the pharmaceutical industry rightly focused on efforts to minimize the environmental impact of drug production, the needle has now shifted. There are signs that companies not only understand that it represents one of the world’s biggest challenges moving forward, but also that they are starting to incorporate sustainability practices into a much broader suite of operations.
  • Brochure Aspen API Product catalogue

    Find out our complete API offering including APIs under development.
  • News Pharmaceutical shortages open up debate on reshoring of API manufacturing

    Panel at CPhI Festival of Pharma discusses options for companies to ensure robust supply chains and reduce overseas supply dependency
  • News Upgrading and expansion of HCG API manufacturing completed

    Aspen Oss has completed a major upgrading and expansion project at its hCG manufacturing facility in Boxtel, the Netherlands; an extensive project that was started in 2017.
  • News Successful ANVISA inspection on Heparin Sodium

    The Brazilian authorities – ANVISA – have inspected the Aspen Oss facilities with a special focus on Heparin Sodium.
  • Brochure Our (highly potent) API development and manufacturing capabilities

    Did you know that we have a history of almost 100 years in the production of complex, highly potent APIs (HPAPIs)? Aspen API works from a deeply rooted and pro-active quality culture. Our facilities are successfully inspected and approved by governmental authorities such as the US FDA, EDQM, PMDA, and others. Serving for many years a stable customer portfolio including global multinationals, generic manufacturers and innovative new tech start-ups, we understand what you need in an API partner. Our expertise and capability to develop, scale-up and commercially manufacture your API, will ensure that you will be working with a reliable high quality partner. At the same time we establish a strong technical foundation for your project success.
  • Brochure Our peptide development and manufacturing capabilities

    Did you know that we have more than 50 years of peptide experience at Aspen API? We have extensive know-how of and experience in both solution and solid-phase synthesis. In addition we have developed a patented method for a green and large scale manufacturing of peptides in solution called Green Continuous Liquid Phase Peptide Synthesis (GC-LPPS).
  • Video Roundtable - Impact of API Globalisation on Drug Shortages

    This Roundtable will feature a high-level panel discussion from industry experts, with numerous opportunities for audience interaction – polls, Q&A and break-out networking sessions. A great opportunity to deep-dive into specific topics, discuss opinions and gather insights from the wider pharma community. Good quality Active Pharmaceutical Ingredients (API) are core to the manufacturing of effective and safe essential drugs. Only a limited number of large manufacturers of finished pharmaceutical products have their own API manufacturing capabilities, and very few have the capacity to manufacture all the required APIs in-house - meaning many rely on foreign sources. As an essential part of the pharmaceutical value chain, API producers are actively looking for solutions that can address the root causes of this issue and set a contingency plan. However, the COVID-19 outbreak has revived fears over acute drug shortages in several countries, sparking calls to repatriate the production of pharmaceutical ingredients to home soil. • Strategies, proactive and structural actions to prevent further drug shortages • The role of the growing globalization of the API pharmaceutical market and safeguard of the pharmaceutical Supply Chain in a Global Economy • Incentives and Challenges to increase local production of drugs and API • Competitiveness of the market, assessing the risk that manufacturers or traders in monopolizing parts of the API market • EU APIs supply chain: overview and consideration for the future Aired as part of the CPhI Festival of pharma

Recommended products